Overview
Lobbying Costs
17,500€
Financial year: Jan 2014 - Jan 2015
Lobbyists (Full time equivalent)
1 Fte (4)
Lobbyists with EP accreditation
0
High-level Commission meetings
8
Lobbying Costs over the years
-
Info
European Organisation for Research and Treatment of Cancer (EORTC)
EU Transparency Register
70539554035-46 First registered on 20 Aug 2010
Goals / Remit
Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a non-profit international cancer research organisation under Belgian Law. The EORTC is recognised as scientific research institution and as non-profit clinical trial sponsor by the Belgian State. The EORTC mission is to improve the standard of cancer treatment in Europe through the development of innovative new drugs and to test more effective therapeutic strategies using commercially available drugs, surgery, or radiotherapy. The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. This is accomplished mainly by conducting international large, multicentre, prospective, randomised, phase III clinical trials.
EORTC clinical research trials are conducted in a network of over 300 participating institutions located in 32 countries in which more than 2,900 clinicians and scientists collaborate on a voluntary basis. More than 6,000 cancer patients are entered into EORTC multidisciplinary trials each year. Some 35 EORTC trials are permanently open to patient entry. The activities of the EORTC are peer reviewed by the US National Cancer Institute. All EORTC protocols are written and conducted in accordance with international standards for ethics: the declaration of Helsinki, Good Clinical Practice guidelines approved by the International Conference on Harmonization.
Independent clinical research is the only way to guarantee an objective evaluation and to establish optimal therapeutic strategies on a multidisciplinary base. However, there is no clinical research possible without collaboration with the industry because of the need for access to innovative new drugs and funding, etc. In order to preserve EORTC independence, EORTC studies must comply with the following basic requirements 1) Clinical study protocol must undergo EORTC pee-review procedures. Input of the academics in the design and the control arm. 2) The clinical study database must be under the full control of EORTC 3) Study primary endpoints must be analysed by independent statistician and reviewed by an Independent Data Monitoring Committee 4) Study results must be published in scientific journal 5) the study bio-samples must be under the custodianship of EORTC.
Located in Brussels, the EORTC Headquarters is a unique facility in Europe. It provides scientific, legal, logistic and administrative support to the clinical and translational research activities of the EORTC cooperative groups (protocol development, data management, statistical analysis, new drugs development, translational research, physical and virtual biobanking, advanced imaging, quality of life, regulatory and ethical affairs management, training, Pharmacovigilance and Quality Assurance). The EORTC Headquarters staff is constituted by 180 highly experienced and trained professionals. Since 1991, the EORTC Fellowship Program has allowed more than 100 medical doctors, statisticians and health scientists from all over the world to do research project at the EORTC. The EORTC is offering a wide range of training for clinical research professionals ranging from GCP to clinical research methodology.Main EU files targeted
- REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.
- Data Protection Regulation.
- Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.Address
Head Office
avenue Mounier, 83
Brussels 1200
BELGIUM -
People
Total lobbyists declared
4
Employment time Lobbyists 25% 4 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Mr Stephane Lejeune (EU Programme Coordinator)
Person with legal responsibility
Mr Denis Lacombe (Director General)
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
European CanCer Organisation
European Forum for Good Clinical Practice
European Platform for Patients' Organisations, Science and Industry
European Alliance for Personnalised Medicine
European Association for NeuroOncology
European Association of Urology
European School of Oncology
European Association of Urology
American Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
European Society for Medical Oncology
American Society for Therapeutic Radiology and Oncology
International Society of Geriatric Oncology
International Society of Pediatric Oncology
International Union Against Cancer
International Network for Cancer Research and Treatment
Organisation of European Cancer Institutes
European Oncology Nursing SocietyMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2014 - Jan 2015
Lobbying costs for closed financial year
17,500€
EU grant income for closed financial year
435,018 € (Source: FP7)
Other financial info
The EORTC is funded through several sources including the EORTC Charitable Trust providing a core grant which is mainly supported by numerous national cancer leagues.
Since 1972, the US National Cancer Institute (NCI) has provided support to EORTC Headquarters, and with this support a close scientific collaboration has been maintained to promote transatlantic research projects.
Core grants from the Fonds Cancer, FOCA (BE) provide support for the EORTC Headquarters staff. EORTC Headquarters also receives grants allocated by BELSPO (the Belgian Federal Science Policy Office) and by the Belgian National Lottery.
Funding for the Fellowship Programme is provided by the EORTC Charitable Trust, Fonds Cancer, FOCA (BE), the Koningin Wilhelmina Fund, KWF (NL), and several leagues including La Ligue Nationale contre le Cancer (FR) and the Vlaamse Liga tegen Kanker, VLK (BE).
In addition, grants for EORTC research projects are received from the European Commission underthe 7th Framework Programmes.
Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry sponsorship is also provided in the form of “unrestricted grants” for EORTC conferences.
The finances of the EORTC include all accounts from the EORTC Headquarters as well as all EORTC Groups and Task Forces. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.
-
EU Structures
Groups (European Commission)
EU Expert Group on Cancer Control
ACC
None
Groups (European Parliament)
None
Communication activities
Participation in workshops and conference. Position statement in collaboration with stakeholders groups such European Alliance for Personalised Medicine.
Other activities
- Revision of the Clinical Trials Directive 2001/20/EC
- Support to international investigator-driven clinical trials
- Human biological material for use in research
- Data protection
Keywords: Health, cancer, clinical research, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, insurances, quality of life, funding, new generation sequencing, molecular screening platform, health economic, Health technology assessment, survivorship, adaptive licensing.- Meetings
Meetings
8 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 11 Mar 2022 Location Brussels, virtual Subject Discussion on Europe's Beating Cancer Plan and breast cancer Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 24 Feb 2021 Location Brussels - virtual meeting Subject Exchange of views on Europe’s Beating Cancer Plan, the EU Pharmaceutical Strategy and the availability of medicines. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 03 Nov 2020 Location Brussels - virtual call Subject Exchange of views on Europe’s Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 19 Feb 2020 Location Brussels Subject challenges of documenting robust evidence for the use of cancer treatments DG Health and Food Safety Attending - Anne Bucher (Director-General)
-
Date 05 Feb 2020 Location Brussels Subject Discussion on Cancer and Europe's Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 03 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - European Society of Cardiology
- European Union of General Practitioners / Family Physicians (Union Européenne des Médecins Omnipraticiens / Médecins de Famille)
- Standing Committee of European Doctors
- The European Association of Hospital Pharmacists
- Phamaceutical Group of the European Union
- European Forum for Primary Care
- European Society for Medical Oncology (ESMO)
- European Hospital and Healthcare Federation
- European Public Health Association
-
Date 16 Apr 2018 Location Brussels Subject Discussion Cancer Research DG Health and Food Safety Attending - Xavier Prats Monné (Director-General)
-
Date 05 May 2017 Location Brussels Subject Clinical research Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Meetings